NCT07042295 2026-04-17
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
17 trialsNCT05379595 2026-04-13
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT05498428 2026-04-13
PALOMA-2
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06120140 2026-04-13
COCOON
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06385080 2026-04-13
OrigAMI-4
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT06662786 2026-04-13
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06667076 2026-04-13
COPERNICUS
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06750094 2026-04-13
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07227025 2026-04-13
KaRAnaSa
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07276399 2026-04-13
OrigAMI-5
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT06507306 2026-02-06
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
Phase 1 Recruiting
NCT07392658 2026-02-06
AMICUTE
Fondazione Ricerca Traslazionale
Phase 2 Recruiting
NCT06116682 2025-12-05
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06632236 2025-04-25
5G-EMERALD
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT06816992 2025-03-20
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT03767075 2024-04-25
BoB
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting